Rivaroxaban versus Warfarin in Patients with Mechanical Heart Valve: Rationale and Design of the RIWA Study

Rivaroxaban versus Warfarin in Patients with Mechanical Heart Valve: Rationale and Design of the RIWA Study

Abstract Introduction Mechanical heart valves (MHV) are extremely durable, but they require permanent use of anticoagulation to prevent thromboembolic events. The only approved therapeutic options are vitamin K antagonists (VKAs), such as warfarin. As a drug class, clinical management is difficult,...

Full description

Bibliographic Details
Main Authors: André R. Durães, Yasmin de Souza Lima Bitar, José Admirço L. Filho, Igor S. Schonhofen, Edmundo J. N. Camara, Leonardo Roever, Hugo E. D. P. Cardoso, Kevan M. Akrami
Format: Article
Language:English
Published: Adis, Springer Healthcare 2018-10-01
Series:Drugs in R&D
Online Access:http://link.springer.com/article/10.1007/s40268-018-0249-5

Internet

http://link.springer.com/article/10.1007/s40268-018-0249-5

Similar Items